골(뼈)과 성장호르몬
Bone and Growth Hormone
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The decade since the initial availability of recombinant growth hormone (GH) has seen an increase in our understanding of the effects of GH on bone. Adult GH deficiency (GHD) is associated with osteopenia, the severity of which is related to three factors: the timing, age of onset and severity of GHD. Epidemiological data suggest that this osteopenia is associated with an increased risk of fracture. The impact of GH replacement therapy on bone mineral density (BMD) appears to be related to a large number of interrelated factors, including the dose and duration of therapy, timing of onset of GHD, skeletal site, degree of osteopenia at baseline, and age and gender of the patient. Overall, the effect of GH replacement on BMD in the majority of patients is beneficial. As yet, however, no data are available that demonstrate a reduction in fracture rate following GH therapy. Therefore, the effects of GH replacement on muscle and bone in GH-deficient individuals are significant and beneficial, although the longer-term effects of GH replacement in terms of reducing the number of fractures and prevention of frailty in old age are not yet established. The effects of GH on bone in GH-replete individuals have been studied less fully. While GH therapy modulates markers of bone resorption and formation, its effects in patients with idiopathic osteoporosis are disappointing, with oestrogen therapy or bisphosphonates proving to be more effective in post-menopausal women. To date, however, there have been no GH treatment trials of adequate duration(longer than 18 months), and it remains possible that longer-term trials may demonstrate more profound effects. unlikely that normal elderly individuals will benefit significantly from GH therapy, but frail individuals or those with musculoskeletal or neuromuscular pathology are potential candidates for study.
Abstract
The decade since the initial availability of recombinant growth hormone (GH) has seen an increase in our understanding of the effects of GH on bone. Adult GH deficiency (GHD) is associated with osteopenia, the severity of which is related to three factors: the timing, age of onset and severity of GHD. Epidemiological data suggest that this osteopenia is associated with an increased risk of fracture. The impact of GH replacement therapy on bone mineral density (BMD) appears to be related to a large number of interrelated factors, including the dose and duration of therapy, timing of onset of GHD, skeletal site, degree of osteopenia at baseline, and age and gender of the patient. Overall, the effect of GH replacement on BMD in the majority of patients is beneficial. As yet, however, no data are available that demonstrate a reduction in fracture rate following GH therapy. Therefore, the effects of GH replacement on muscle and bone in GH-deficient individuals are significant and beneficial, although the longer-term effects of GH replacement in terms of reducing the number of fractures and prevention of frailty in old age are not yet established. The effects of GH on bone in GH-replete individuals have been studied less fully. While GH therapy modulates markers of bone resorption and formation, its effects in patients with idiopathic osteoporosis are disappointing, with oestrogen therapy or bisphosphonates proving to be more effective in post-menopausal women. To date, however, there have been no GH treatment trials of adequate duration(longer than 18 months), and it remains possible that longer-term trials may demonstrate more profound effects. unlikely that normal elderly individuals will benefit significantly from GH therapy, but frail individuals or those with musculoskeletal or neuromuscular pathology are potential candidates for study.
참고문헌 (48)
- Bouillon R, "Growth hormone and bone", Horm Res, 36, pp.49~55 (1991)
- Swolin D, "Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells", J Endocrinol, 149, pp.397~403 (1996)
- Hayden JM, "The insulin-like growth factor system and the coupling of formation to resorption", Bone, 17, pp.93~98 (1995)
- Blum WF, "A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency", J Clin Endocrinol Metab, 70, pp.1292~1298 (1990)
- Mohan S, "Studies on regulation of insulin-like growth factor binding protein (IGFBP) -3 and IGFBP-4 production in human bone cells", Acta Endocrinol (Copenh), 127, pp.555~564 (1992)
- Bautista CM, "Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone", Biochem Biophys Res Commun, 176, pp.756~763 (1991)
- Chen TL, "Further characterization of insulin-like-growth factor binding proteins in rat osteoblast-like cell cultures: modulation by 17 beta-estradiol and human growth hormone", Endocrinology, 128, pp.2489~2496 (1991)
- Leung K, "Insulin-like growth factor I and insulin down-regulate growth hormone (GH) receptors in rat osteoblasts: evidence for a peripheral feedback loop regulating GH action", Endocrinology, 137, pp.2694~2702 (1996)
- Nishiyama K, "Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation", Endocrinology, 137, pp.35~41 (1996)
- Fiorelli G, "Characterization and function of the receptor for IGF-I in human preosteoclastic cells", Bone, 18, pp.269~276 (1996)
- RansjöM, "Growth hormone inhibits formation of osteoclast-like cells in mouse bone marrow cultures", J Bone Miner Res, 11 Suppl, pp.394~ (1996)
- Stracke H, "Effect of growth hormone on osteoblasts and demonstration of somatomedin-C", IGF I in bone organ culture, 1984, pp.107, 16~24
- Johansson AG, "The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I", Journal of Internal Medicine, 232, pp.447~452 (1992)
- Ljunghall S, "Low plasma levels of insulin-like growth factor 1(IGF-1) in male patients with idiopathic osteoporosis", Journal of Internal Medicine, 232, pp.59~64 (1992)
- Harris WH, "Effect of growth hormone on skeletal mass in adult dogs", Nature, 223, pp.403~404 (1969)
- Mann DR, "Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration", Journal of Clinical Endocrinology and Metabolism, 74, pp.1263~1269 (1992)
- Zilkens KW, "The influence of growth hormone in healing of fractures in rats (author’s transl)", Unfallheilkunde, 83, pp.446~449 (1980)
- Bak B, "The stimulating effect of growth hormone on fracture healing is dependent on onset and duration of administration", Clin Orthop, 264, pp.295~301 (1991)
- Bak B, "The effect of aging on fracture healing in the rat", Calcif Tissue Int, 45, pp.292~297 (1989)
- Hedner E, "Systemically and locally administered growth hormone stimulates bone healing in combination with osteopromotive membranes: an experimental study in rats", J Bone Miner Res, 11, pp.1952~1960 (1996)
- Herold HZ, "The effect of growth hormone on the healing of experimental bone defects", Acta Orthop Scand, 42, pp.377~384 (1971)
- "1961", 43
- Hao Y, "Effects of recombinant human growth hormone (r-hGH) on experimental osteoporotic fracture healing", Chin J Traumatol, 4(2), pp.102~105 (2001)
- Yeo AL, "Frailty and the biochemical effects of recombinant human growth hormone in women after surgery for hip fracture", Growth Horm IGF Res, 13, pp.361~370 (2003)
- Schmidmaier G, "Improvement of fracture healing by systemic administration of growth hormone and local application of insulinlike growth factor-1 and transforming growth factorbeta1", Bone, 31, pp.165~172 (2002)
- Kasukawa Y, "The anabolic effects of GH", IGF system on bone, 2004, pp.10, 2577~1592
- Zadik Z, "The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals", J Clin Endocrinol Metab, 60, pp.513~516 (1985)
- Landin-Wilhelmsen K, "Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin", Clin Endocrinol (Oxf), 41, pp.351~357 (1994)
- Ljunghall S, "Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis", J Intern Med, 232, pp.59~64 (1992)
- Brixen K, "Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study", J Bone Miner Res, 10, pp.1865~1874 (1995)
- Ho KK, "Sex steroid regulation of growth hormone secretion and action", Horm Res, 45, pp.67~73 (1996)
- Friend KE, "Both oral and transdermal estrogen increase growth hormone release in postmenopausal women--a clinical research center study", J Clin Endocrinol Metab, 81, pp.2250~2256 (1996)
- Rudman D, "Effects of human growth hormone in men over 60 years old", N Engl J Med, 323, pp.1~6 (1990)
- Aloia JF, "Treatment of osteoporosis with calcitonin, with and without growth hormone", Metabolism, 34, pp.124~129 (1985)
- Marcus R, "Effects of short term administration of recombinant human growth hormone to elderly people", Journal of Clinical Endocrinology and Metabolism, 70, pp.519~527 (1990)
- Brixen K, "A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers", Journal Bone and Mineral Research, 5, pp.609~618 (1990)
- Rudman D, "Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old", New England Journal of Medicine, 323, pp.1~6 (1990)
- Holloway L, "Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women", J Clin Endocrinol Metab, 79, pp.470~479 (1994)
- Ebeling PR, "Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women", J Clin Endocrinol Metab, 77, pp.1384~1387 (1993)
- Canalis E, "Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid- induced osteoporosis", J Clin Endocrinol Metab, 81, pp.3441~3447 (1996)
- Tanaka H, "Does growth hormone treatment prevent corticosteroid-induced osteoporosis?", Bone, 18, pp.493~494 (1996)
- Sanchez CP, "Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids", J Bone Miner Res, 10, pp.2~6 (1995)
- Giustina A, "Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone", J Clin Endocrinol Metab, 80, pp.122~129 (1995)
- Johansson AG, "Insulin-like growth factor I stimulates bone turnover in osteoporosis", Lancet, 339, pp.1619~ (1992)
- Ghiron LJ, "Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women", J Bone Miner Res, 10, pp.1844~1852 (1995)
- Johansson AG, "Insulin-like growth factor I stimulates bone turnover in osteoporosis", Lancet, 339, pp.1619~ (1992)
- Grinspoon SK, "Effects of rhIGF-I administration on bone turnover during short-term fasting", J Clin Invest, 96, pp.900~906 (1995)
- Bagi CM, "Benefit of systemically administered rhIGF-I and rhIGF-I", IGFBP-3 on cancellous bone in ovariectomized rats, 1994, pp.9, 1301~1312